Children's Health Defense An “elite” and influential group of obesity specialists over the last decade pocketed at least $25.8 million in payments from Novo Nordisk, maker of weight loss drugs Wegovy and Saxenda, in exchange for promoting the drugs in their lectures, treatment guidelines, clinics and medical societies, according to an investigation by Reuters.
An “elite” and influential group of obesity specialists over the last decade pocketed at least $25.8 million in payments from Novo Nordisk, maker of weight loss drugs Wegovy and Saxenda, in exchange for promoting the drugs in their lectures, treatment guidelines, clinics and medical societies, according to an investigation by Reuters.
“Those payments are part of a campaign to convince U.S. doctors to make Wegovy one of the most widely prescribed drugs in history — and to persuade skeptical insurers to pay for it,” according to the report.
Wegovy and Saxenda have rapidly transformed the treatment of obesity in the U.S., with a boom in prescriptions so big in 2023 that JP Morgan doubled its 10-year sales projection, predicting sales of $71 million for the drugs by 2032.
Read Full Article Here…(childrenshealthdefense.org)
Home | Caravan to Midnight (zutalk.com)
Live Stream + Chat (zutalk.com)
